Merck Cozaar Approval Nod For Nephropathy Gets Boost From Avapro Data
Executive Summary
An advisory committee recommendation for Merck's Cozaar in the treatment of nephropathy in type 2 diabetes patients reflects supportive evidence from Bristol-Myers Squibb/Sanofi's Avapro data.
You may also be interested in...
Merck Cozaar, Bristol Avapro Gain Nephropathy Indication On Shared Data
FDA approvals of Merck's Cozaar (losartan) and Bristol/Sanofi's Avapro (irbesartan) for the treatment of nephropathy in type 2 diabetes patients are based on data shared by the companies under a reciprocal agreement
Merck Cozaar, Bristol Avapro Gain Nephropathy Indication On Shared Data
FDA approvals of Merck's Cozaar (losartan) and Bristol/Sanofi's Avapro (irbesartan) for the treatment of nephropathy in type 2 diabetes patients are based on data shared by the companies under a reciprocal agreement
Merck Cozaar Nephropathy Label Should Include Cardioprotection Uncertainty
Merck's Cozaar labeling for type 2 diabetic nephropathy should convey questions about cardioprotective effect and caution about substitution for ACE inhibitors, FDA's Cardiovascular & Renal Drugs Advisory Committee suggested at its April 12 meeting